The 2026 IMS Annual Meeting will showcase groundbreaking research across basic, translational, and clinical domains in MM and related disorders
In addition to core sessions spanning newly diagnosed MM, the increasingly complex landscape of treatment at first relapse, the advancing frontier of blood-based technologies, and the latest on immune system monitoring and toxicity management, the 2026 International Myeloma Society (IMS) Annual Meeting will spotlight:

• An exciting and highly anticipated IMS/IMWG update on the definition of cure in myeloma

• Plenary Abstract presentations on:

  • The phase 3 CERVINO trial data for the investigational, second-generation BCMA×CD3 bispecific etentamig

  • Long-term data from the practice-changing PERSEUS trial

  • Findings from the phase 3 EXCALIBER-RRMM study of the novel investigational CELMoD iberdomide with daratumumab and dexamethasone

  • First-in-human results for an in vivo BCMA/CD19 dual-targeting CAR-T

  • A potential new therapeutic vulnerability in t(4;14) MM

  • A risk refinement approach in the UKMRA OPTIMUM trial

• Oral Abstract presentations, including:

  • Post hoc analyses and updated findings from MajesTEC-3

  • Quality of life data from the UKMRA RADAR trial focused on high-risk MM

  • Novel maintenance strategies based on doublets (isatuximab-iberdomide in MIDAS and daratumumab-iberdomide in IBEX) or guided by MRD (GEM2014MAIN)

  • First-in-human findings for several investigational agents, including dual-targeting and in vivo CAR-T therapies and new bispecific/trispecifc T-cell engagers

  • High-resolution omics data mapping the tumor microenvironment and genomic/epigenomic landscape in MM

• And special IMS joint sessions with the AACR, EHA, and patient groups

• There is still time to register to attend either in-person or virtual participation.

NICE backs first-line daratumumab quadruplet in transplant-eligible NDMM
The UK’s National Institute for Health and Care Excellence (NICE) issued Final Draft Guidance (FDG) recommending daratumumab in combination with bortezomib, lenalidomide and dexamethasone (Dara-VRd) followed by daratumumab plus lenalidomide maintenance therapy for previously untreated multiple myeloma (MM) in transplant-eligible patients, according to a press release. The FDG also supports use of Dara-VRd for patients treated with daratumumab-bortezomib-thalidomide-dexamethasone induction and consolidation who are yet to start maintenance therapy. Moreover, the FDG outlines recommendations on incorporation of an MRD-guided approach to treatment.

Risk-stratified treatment yields sustained PFS and OS benefits
In the phase 2 OPTIMUM trial, comparing intensified induction, extended consolidation, and maintenance therapy after autologous stem-cell transplantation with an external comparator arm in patients with high-risk MM, the risk-stratified treatment strategy improved PFS, PFS2, and OS at five years follow-up. These data, reported in The Lancet Oncology, extend the previously reported improvement in the primary endpoint, 18-month PFS.

Fixed-duration teclistamab combination improves PFS in high-risk SMM
In patients with high-risk smoldering multiple myeloma (SMM), fixed-duration treatment with teclistamab in combination with lenalidomide and dexamethasone demonstrated higher two-year progression-free survival rates, 92%, compared with 49% in patients who received lenalidomide and dexamethasone alone. These findings from the phase 2 ImmunoPRISM trial were reported in Nature Medicine.